The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study
Abstract
BACKGROUND Investigations of myelin oligodendrocyte glycoprotein (MOG) antibodies are usually focused on demyelinating syndromes, but the entire spectrum of MOG antibody-associated syndromes in children is unknown. In this study, we aimed to determine the frequency and distribution of paediatric demyelinating and encephalitic syndromes with MOG antibodies, their response to treatment, and the phenotypes associated with poor prognosis. METHODS In this prospective observational study, children with demyelinating syndromes and with encephalitis other than acute disseminated encephalomyelitis (ADEM) recruited from 40 secondary and tertiary centres in Spain were investigated for MOG antibodies. All MOG antibody-positive cases were included in our study, which assessed syndromes, treatment and response to treatment (ie, number of relapses), outcomes (measured with the modified Rankin scale [mRS]), and phenotypes associated with poor prognosis. We used Fisher's exact and Wilcoxon rank sum tests to analyse clinical features, and survival Cox regression to analyse time to antibody negativity. FINDINGS Between June 1, 2013, and Dec 31, 2018, 239 children with demyelinating syndromes (cohort A) and 296 with encephalitis other than ADEM (cohort B) were recruited. 116 patients had MOG antibodies, including 94 (39%) from cohort A and 22 (7%) from cohort B; 57 (49%) were female, with a median age of 6·2 years (IQR 3·7-10·0). Presenting syndromes in these 116 patients included ADEM (46 [68%]), encephalitis other than ADEM (22 [19%]), optic neuritis (20 [17%]), myelitis (13 [11%]), neuromyelitis optica spectrum disorders (six [5%]), and other disorders (nine [8%]). Among the patients with autoimmune encephalitis in cohort B (n=64), MOG antibodies were more common than all neuronal antibodies combined (22 [34%] vs 21 [33%]). After a median follow-up of 42 months (IQR 22-67), 33 (28%) of the 116 patients had relapses, including 17 (17%) of 100 diagnosed at first episode. Steroids, intravenous immunoglobulin, or plasma exchange were used in 100 (86%) patients at diagnosis, and 32 (97%) of 33 at relapses. Rituximab was mainly used at relapses (11 [33%]). 99 (85%) of 116 patients had substantial recovery (mRS <2) and 17 (15%) moderate to severe deficits (mRS >2; one died). Phenotypes of poor prognosis included ADEM-like relapses progressing to leukodystrophy-like features, and extensive cortical encephalitis evolving to atrophy. Time to antibody negativity was longer in patients with relapses (HR 0·18, 95% CI 0·05-0·59). INTERPRETATION The spectrum of paediatric MOG antibody-associated syndromes is wider than previously reported and includes demyelinating syndromes and encephalitis. Recognition of these disorders has important clinical and prognostic implications. FUNDING Mutua Madrileña Foundation; ISCIII-Subdirección General de Evaluación y Fomento de la Investigación Sanitaria; Fondo Europeo de Desarrollo Regional; Pediatrics Spanish Society; Departament de Salut, Generalitat de Catalunya; Marato TV3 Foundation; Red Española de Esclerosis Múltiple; La Caixa Foundation; and Fundació CELLEX.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167
Self-citationInterobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Venkatesan, A., Tunkel, A. R., Bloch, K. C., Lauring, A. S., Sejvar, J., Bitnun, A., Stahl, J.-P., Mailles, A., Drebot, M., Rupprecht, C. E., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit458 · Cited by 1,197
Krupp, L. B., Tardieu, M., Amato, M. P., Banwell, B., Chitnis, T., Dale, R. C., Ghezzi, A., Hintzen, R., Kornberg, A., Pohl, D., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513484547 · Cited by 1,130
AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location
Lai, M., Hughes, E. G., Peng, X., Zhou, L., Gleichman, A. J., Shu, H., Matà, S., Kremens, D., Vitaliani, R., Geschwind, M. D., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21589 · Cited by 813
Self-citationClinical presentation and prognosis in MOG-antibody disease: a UK study
Jurynczyk, M., Messina, S., Woodhall, M. R., Raza, N., Everett, R., Roca-Fernandez, A., Tackley, G., Hamid, S., Sheard, A., Reynolds, G., et al. (2017) · Brain · doi:10.1093/brain/awx276 · Cited by 740
Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
Ogawa, R., Nakashima, I., Takahashi, T., Kaneko, K., Akaishi, T., Takai, Y., Sato, D. K., Nishiyama, S., Misu, T., Kuroda, H., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000322 · Cited by 436
Hacohen, Y., Wong, Y. Y., Lechner, C., Jurynczyk, M., Wright, S., Konuskan, B., Kalser, J., Poulat, A. L., Maurey, H., Ganelin-Cohen, E., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4601 · Cited by 423
Cited by
Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., Ramanathan, S., Waters, P., Tenembaum, S., Graves, J. S., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00431-8 · Cited by 1,246
Self-citationMyelin-oligodendrocyte glycoprotein antibody-associated disease
Marignier, R., Hacohen, Y., Cobo-Calvo, A., Pröbstel, A.-K., Aktas, O., Alexopoulos, H., Amato, M.-P., Asgari, N., Banwell, B., Bennett, J., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00218-0 · Cited by 543
Sechi, E., Cacciaguerra, L., Chen, J. J., Mariotto, S., Fadda, G., Dinoto, A., Lopez-Chiriboga, A. S., Pittock, S. J., & Flanagan, E. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.885218 · Cited by 325
Cobo‐Calvo, A., Ruiz, A., Rollot, F., Arrambide, G., Deschamps, R., Maillart, E., Papeix, C., Audoin, B., Lépine, A. F., Maurey, H., et al. (2021) · Annals of Neurology · doi:10.1002/ana.25909 · Cited by 270
Self-citationPathogen and Antibody Identification in Children with Encephalitis in Myanmar
Galardi, M. M., Sowa, G. M., Crockett, C. D., Rudock, R., Smith, A. E., Shwe, E. E., San, T., Linn, K., Aye, A. M. M., Ramachandran, P. S., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26560 · Cited by 14
Self-citation
Metadata
- Authors
- Armangue, T., Olivé-Cirera, G., Martínez-Hernandez, E., Sepulveda, M., Ruiz-Garcia, R., Muñoz-Batista, M., Ariño, H., González-Álvarez, V., Felipe-Rucián, A., Jesús Martínez-González, M., Cantarín-Extremera, V., Concepción Miranda-Herrero, M., Monge-Galindo, L., Tomás-Vila, M., Miravet, E., Málaga, I., Arrambide, G., Auger, C., Tintoré, M., Montalban, X., Vanderver, A., Graus, F., Saiz, A., Dalmau, J., Alcantud, A., Aguilera-Albesa, S., Alvarez Demanuel, D., Alvarez Molinero, M., Aquino Fariña, L., Arrabal, L., Arriola-Pereda, G., Aznar-Laín, G., Benavides-Medina, M., Bermejo, T., Blanco-Lago, R., Caballero, E., Calvo, R., Camacho Salas, A., Conejo-Moreno, D., Delgadillo-Chilavert, V., Elosegi-Castellanos, A., Esteban Canto, V., Fernández-Ramos, J., Garcia-Puig, M., García-Ribes, A., Gómez-Martín, H., Gonzalez-Barrios, D., González-Gutiérrez-Solana, L., Jimena-Garcia, S., Jiménez-Legido, M., Juliá-Palacios, N., López-Laso, E., Martí-Carrera, I., Martínez González, M., Martín-Viota, L., Mattozi, S., Maqueda-Castellote, E., Mendibe, M. D. M., Mora-Ramírez, M. D., Muñoz-Cabello, B., Navarro-Morón, J., Nunes-Cabrera, T., Orellana, G., Pujol-Soler, B., Querol, L., Ramírez, A., Rodriguez-Lucenilla, M. I., Ruiz, C., Soto-Insuga, V., Toledo Bravo de Laguna, L., Turon-Viñas, E., Vázquez-López, M., & Villar-Vera, C.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 19
- Issue
- 3
- Pages
- 234-246
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W3004592781
- Cited by
- 334
- References
- 27
- FWCI
- 28.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. https://app.cochat.ai/papers/10.1016/s1474-4422(19)30488-0
- The paper
- Armangue, T., Olivé-Cirera, G., Martínez-Hernandez, E., Sepulveda, M., Ruiz-Garcia, R., Muñoz-Batista, M., Ariño, H., González-Álvarez, V., Felipe-Rucián, A., Jesús Martínez-González, M., Cantarín-Extremera, V., Concepción Miranda-Herrero, M., Monge-Galindo, L., Tomás-Vila, M., Miravet, E., Málaga, I., Arrambide, G., Auger, C., Tintoré, M., . . . Villar-Vera, C. (2020). Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(19)30488-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.